Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 2018-03, Vol.154 (4), p.1201-1202
Hauptverfasser:	Papamichael, Konstantinos, Osterman, Mark T., Siegel, Corey A., Melmed, Gil Y., Dubinsky, Marla C., Colombel, Jean-Frederic, Hanauer, Stephen B., Cheifetz, Adam S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Biological Products - adverse effects Biological Products - therapeutic use Drug Monitoring - methods Drug Monitoring - standards Gastrointestinal Agents - adverse effects Gastrointestinal Agents - therapeutic use Humans Inflammatory Bowel Diseases - diagnosis Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - immunology Predictive Value of Tests Standard of Care Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!